Abstract
Background
The aim of this study was to evaluate the efficacy and safety of a combined chemotherapy regimen, gemcitabine and cisplatin (GC), in the treatment of advanced urothelial carcinomas.
Methods
Fifty-five patients with advanced urothelial cancer were treated with GC (gemcitabine 1000 mg/m2 on days 1, 8, and 15; cisplatin 70 mg/m2 on day 2) every 28 days. The median follow-up was 30 months (range, 3 to 57 months).
Results
With the GC therapy, 35 of the 55 patients (63.6%) showed an objective response, with 7 (12.7%) achieving a clinical complete response (CR) and 28 (50.9%), a partial response (PR). GC therapy had a better impact on metastases in the lung and lymph nodes than on metastases in the liver and bone. Lung and lymph nodes showed objective responses of 64.7% and 65.8%, respectively. Eight of the 20 patients (40.0%) who had previously been treated with other regimens showed an objective response, with 1 achieving a CR and 7 achieving a PR. In the 47 patients with metastasis, the median time to progression was 7.0 months (range, 2 to 49 months), and the median overall survival was 12.0 months (range, 3 to 49 months). The 2-year survival rate was 80.0% in the CR group, while it was 55.1% in the PR group and 10.0% in the progressive disease (PD) group. The toxicities associated with GC, particularly mucositis, anorexia, and alopecia, were quite mild. Grade 3–4 toxicity was primarily hematological, including anemia (27.3%), neutropenia (32.7%), and thrombocytopenia (43.6%).
Conclusion
GC is considered to be a highly effective and well-tolerated regimen for the treatment of advanced urothelial carcinomas, with moderate toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
CN Sternberg A Yagoda HI Scher et al. (1989) ArticleTitleMethotrexate, vinblastine, doxorubicine, and cisplatin for advanced transitional cell carcinoma of the urothelium Cancer 64 2448–2458 Occurrence Handle2819654 Occurrence Handle10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7 Occurrence Handle1:STN:280:By%2BD2MfktVY%3D
I Tannock M Gospodarowicz J Connolly et al. (1989) ArticleTitleM-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience J Urol 142 289–292 Occurrence Handle2746745 Occurrence Handle1:STN:280:BiaA3M7ms1I%3D
LW Hertel GB Boder JS Kroin et al. (1990) ArticleTitleEvaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) Cancer Res 50 4417–4422 Occurrence Handle2364394 Occurrence Handle1:CAS:528:DyaK3cXkvFWjtb4%3D
SB Saxman KJ Propert LH Einhorn et al. (1990) ArticleTitleLong term follow up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 15 2564–2569
CL Logothetis FH Dexeus A Sella et al. (1990) ArticleTitleEscalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin- cisplatin plus ongoing unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor J Natl Cancer Inst 82 667–672 Occurrence Handle2181151 Occurrence Handle10.1093/jnci/82.8.667 Occurrence Handle1:STN:280:By%2BB3cvlslc%3D
V Lorusso CF Pollera M Antimi et al. (1998) ArticleTitleA phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer Eur J Cancer 34 1208–1212 Occurrence Handle9849481 Occurrence Handle10.1016/S0959-8049(98)00030-6 Occurrence Handle1:CAS:528:DyaK1cXltlCgsr4%3D
WM Stadler T Kuzel B Roth et al. (1997) ArticleTitlePhase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer J Clin Oncol 15 3394–3398 Occurrence Handle9363871 Occurrence Handle1:CAS:528:DyaK2sXnsVensb0%3D
BJ Roth D Bajorin (1995) ArticleTitleAdvanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) World J Urol 153 894–900 Occurrence Handle1:STN:280:ByqC2Mnms1M%3D
H von der Maase SW Hansen JT Roberts et al. (2000) ArticleTitleGemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 17 3068–3077
D Kaufman D Raghavan M Carducci et al. (2000) ArticleTitlePhase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer J Clin Oncol 18 1921–1927 Occurrence Handle10784633 Occurrence Handle1:CAS:528:DC%2BD3cXjvVentr0%3D
MJ Moore E Winquist N Murray et al. (1999) ArticleTitleGemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 17 2876–2880 Occurrence Handle10561365 Occurrence Handle1:CAS:528:DyaK1MXmtlWqsr8%3D
InstitutionalAuthorNameWorld Health Organization (1979) WHO Handbook for reporting results of cancer treatment WHO Geneva
S Hoshi C Ohyama K Ono et al. (2004) ArticleTitleGemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report Int J Clin Oncol 9 126–129 Occurrence Handle10.1007/s10147-003-0379-8
HB Grossman RB Natale CM Tangen et al. (2003) ArticleTitleNeoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 859–866 Occurrence Handle12944571 Occurrence Handle10.1056/NEJMoa022148 Occurrence Handle1:CAS:528:DC%2BD3sXmvVSnu7Y%3D
InstitutionalAuthorNameAdvanced Bladder Cancer Meta-analysis Collaboration (2003) ArticleTitleNeoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 1927–1934 Occurrence Handle10.1016/S0140-6736(03)13580-5
Y Matsui H Nishiyama J Watanabe et al. (2005) ArticleTitleThe current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan J Clin Oncol 10 133–138
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ozawa, A., Tanji, N., Ochi, T. et al. Gemcitabine and cisplatin for advanced urothelial carcinomas: the Ehime University Hospital experience. Int J Clin Oncol 12, 279–283 (2007). https://doi.org/10.1007/s10147-007-0678-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-007-0678-6